La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Kiniksa Pharmaceuticals International Gestione
Gestione criteri di controllo 4/4
Kiniksa Pharmaceuticals International's Il CEO è Sanj Patel, nominato in Jul2015, e ha un mandato di 9.08 anni. la retribuzione annua totale è $ 5.30M, composta da 16.3% di stipendio e 83.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.38% delle azioni della società, per un valore di $ 44.17M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.6 anni e 7.7 anni.
Informazioni chiave
Sanj Patel
Amministratore delegato
US$5.3m
Compenso totale
| Percentuale dello stipendio del CEO | 16.3% |
| Mandato del CEO | 9.1yrs |
| Proprietà del CEO | 2.4% |
| Durata media del management | 3.6yrs |
| Durata media del Consiglio di amministrazione | 7.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 07
Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
Jul 24Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues
Jun 19Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?
Jan 02
Kiniksa's antibody treatment shows clinical benefit in late-stage COVID-19 study
Dec 22Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$5m | US$864k | US$14m |
| Sep 30 2023 | n/a | n/a | -US$7m |
| Jun 30 2023 | n/a | n/a | US$231m |
| Mar 31 2023 | n/a | n/a | US$196m |
| Dec 31 2022 | US$6m | US$835k | US$183m |
| Sep 30 2022 | n/a | n/a | US$143m |
| Jun 30 2022 | n/a | n/a | -US$112m |
| Mar 31 2022 | n/a | n/a | -US$134m |
| Dec 31 2021 | US$7m | US$803k | -US$158m |
| Sep 30 2021 | n/a | n/a | -US$175m |
| Jun 30 2021 | n/a | n/a | -US$189m |
| Mar 31 2021 | n/a | n/a | -US$184m |
| Dec 31 2020 | US$5m | US$780k | -US$161m |
| Sep 30 2020 | n/a | n/a | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$123m |
| Mar 31 2020 | n/a | n/a | -US$122m |
| Dec 31 2019 | US$5m | US$780k | -US$162m |
| Sep 30 2019 | n/a | n/a | -US$173m |
| Jun 30 2019 | n/a | n/a | -US$170m |
| Mar 31 2019 | n/a | n/a | -US$153m |
| Dec 31 2018 | US$7m | US$740k | -US$103m |
| Sep 30 2018 | n/a | n/a | -US$93m |
| Jun 30 2018 | n/a | n/a | -US$85m |
| Mar 31 2018 | n/a | n/a | -US$76m |
| Dec 31 2017 | US$1m | US$700k | -US$65m |
Compensazione vs Mercato: La retribuzione totale di Sanj ($USD 5.30M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 5.62M ).
Compensazione vs guadagni: La retribuzione di Sanj è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Sanj Patel (55 yo)
9.1yrs
Mandato
US$5,297,067
Compensazione
Mr. Sanj K. Patel has been the Chief Executive Officer of Kiniksa Pharmaceuticals International, plc (formerly known as Kiniksa Pharmaceuticals, Ltd.) since July 2015. Before founding Kiniksa Pharmaceutica...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.1yrs | US$5.30m | 2.38% $ 44.7m | |
| Senior VP & COO | 2.6yrs | US$1.75m | 0.18% $ 3.3m | |
| Senior VP & Chief Medical Officer | 8yrs | US$1.79m | 0.067% $ 1.3m | |
| Senior VP & CFO | 3.7yrs | Nessun dato | 0.027% $ 506.9k | |
| Chief Accounting Officer & Group VP of Finance | 4.5yrs | Nessun dato | 0.030% $ 561.6k | |
| Senior Vice President of Technical Operations | 3.6yrs | Nessun dato | Nessun dato | |
| Senior Director of Investor Relations & Corporate Communications | no data | Nessun dato | Nessun dato | |
| Senior VP & Chief Compliance Officer | 3.3yrs | Nessun dato | Nessun dato | |
| SVP, General Counsel & Secretary | 3.6yrs | Nessun dato | Nessun dato | |
| Executive Vice President of Corporate Affairs | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Regulatory Affairs | 3.7yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief Commercial Officer | 2.6yrs | Nessun dato | 0.023% $ 428.6k |
3.6yrs
Durata media
51.5yo
Età media
Gestione esperta: Il team dirigenziale di KNSA è considerato esperto (durata media dell'incarico 3.6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.1yrs | US$5.30m | 2.38% $ 44.7m | |
| Independent Director | 6.5yrs | US$362.66k | 0.013% $ 246.9k | |
| Lead Independent Director | 8.8yrs | US$411.06k | 0.028% $ 522.4k | |
| Independent Director | 7.7yrs | US$380.36k | 0.013% $ 246.9k | |
| Independent Director | 8.8yrs | US$372.55k | 0.013% $ 246.9k | |
| Independent Director | 5.4yrs | US$459.75k | 0.018% $ 339.5k | |
| Independent Director | 4.1yrs | US$365.36k | 0.013% $ 246.9k | |
| Independent Director | 8.8yrs | US$371.96k | 0.0070% $ 131.7k | |
| Chairman of Scientific Advisory Board | no data | Nessun dato | 2.08% $ 38.9m | |
| Independent Director | 6.5yrs | US$365.36k | 0.013% $ 246.9k |
7.7yrs
Durata media
56yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di KNSA sono considerati esperti (durata media dell'incarico 7.7 anni).